Immunotherapy Using HistobulinTM In Psoriasis: A Case Report
preprint
OA: closed
Abstract
Abstract Background: There is no cure for psoriasis. Early treatment using biologics is recommended to improve skin manifestations and reduce systemic inflammation, which leads to comorbidities in various organs.Case Presentation: HistobulinTM therapy was performed on a psoriasis patient who developed the disorder due to allergic rhinitis. Psoriasis was confirmed pathologically by skin biopsy. The patient responded rapidly, and the skin manifestations began to improve after just the first injection. Although the patient showed some temporary aggravation after the third injection, the clinical symptoms and signs improved continuously thereafter and disappeared after the eighth injection. Remission was induced and was evident when the patient showed no symptoms and signs during the subsequent 4 weeks during which time the patient received 4 more injections; afterwards, HistobulinTM therapy was ceased. After treatment, psoriasis did not recur for more than 6 months.Conclusions: HistobulinTM is effective and induces remission in psoriasis patients. HistobulinTM is suggested for curative therapeutics in psoriasis patients, and further basic research and clinical evaluation are necessary.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00